Cytosorbents outlines DrugSorb ATR regulatory appeals and targets core business breakeven as German reorganization drives 22% sales growth
Source: SeekingAlpha
2025-08-08 13:23:38 ET
More on Cytosorbents
- Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript
- Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript
- Cytosorbents outlines plans for DrugSorb-ATR appeal and targets breakeven core business by second half 2025
- Cytosorbents Non-GAAP EPS of -$0.06, revenue of $8.73M misses by $0.28M
- Seeking Alpha’s Quant Rating on Cytosorbents
Read the full article on Seeking Alpha
For further details see:
Cytosorbents outlines DrugSorb ATR regulatory appeals and targets core business breakeven as German reorganization drives 22% sales growth
CytoSorbents Corporation
NASDAQ: CTSO
CTSO Trading
-3.11% G/L:
$0.7101 Last:
14,580 Volume:
$0.744 Open:
CTSO Latest News
March 05, 2026 07:00:00 am
CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
January 12, 2026 07:00:00 am
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update
December 10, 2025 07:00:00 am
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025
November 17, 2025 05:42:00 pm
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
CTSO Stock Data
$42,078,884
58,219,591
2.36%
17
N/A
Medical Equipment & Supplies
Healthcare
US
Princeton
